NAVER D2SF Invests in AI-Driven Precision Medicine Company ImpriMed

ImpriMed combines ex vivo functional testing with multimodal AI to support personalized cancer treatment decisions and drug development The investment is part of ImpriMed's $10 million Series A2 bridge round as the company advances U.S. commercialization and expands into Asia NAVER D2SF...